The purpose of the study is to find out if the under‑skin injection works at least as well as the vein infusion in terms of how the drug moves through the body (pharmacokinetic). Participants are randomly assigned to one of the two ways of receiving the medicine and will visit the clinic regularly for blood tests, imaging scans to see the tumor, and safety checks. The trial lasts for several months, during which any side effects are recorded and managed.

The purpose of the study is to determine whether weekly injections of the drug improve nerve symptoms compared with the placebo. Participants will receive an injection each week for several months and will attend regular visits where doctors will check nerve function using a questionnaire called the mTCNS (a score that rates how severe the nerve problems are). Other questionnaires will also be used, such as the Norfolk QoL-DN (a quality‑of‑life survey for nerve disease), the clinESSDAI and ESSDAI (measures of overall disease activity), the NPQ (a questionnaire about pain), a NRS rating for difficulty thinking, and patient‑ and clinician‑rated impression scales (PGIS, PGIC, CGIS, and CGI). Fatigue will be measured with the FACIT-Fatigue questionnaire.

Throughout the study, safety will be monitored by checking vital signs, heart rhythm, blood tests, and any side effects that may occur. Participants will have the opportunity to report any adverse events, and the study team will evaluate the seriousness of any findings. The overall design allows comparison of the drug’s effect with the placebo while keeping participants and investigators unaware of which treatment is being given.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The purpose of the study is to find out whether the spray can improve the sharpness of vision, known as visual acuity, compared with the placebo. Over several months, participants will use the spray daily and attend regular visits where standard eye tests are performed, such as reading letters on a chart, checking the area that can be seen without moving the eyes (visual field), and an eye scan called optical coherence tomography that measures the thickness of retinal layers. The study follows each person from the start of treatment through the end of the observation period to see how vision changes over time.

The purpose of the study is to determine whether giving a single dose of Tocilizumab before the cancer drug ramantamig can lower the chance of this immune reaction compared with a placebo. Participants are randomly assigned to receive either the active medication or the inactive solution, and neither the medical team nor the participants know which one is given. After the injection, participants receive the cancer treatment and are observed for about four weeks for any signs of the immune reaction or other side effects.

The trial follows a double‑blind design, meaning the assignment is concealed, and it lasts until the end of the monitoring period after the first dose of the cancer drug. Safety checks, blood tests, and regular visits are used to record any problems that arise during the study.

The purpose of the trial is to determine whether the new medicine works as well as, or better than, the standard treatment in patients who have not received prior therapy for this condition. This phase 3 investigation uses a randomized, open-label design, meaning participants are assigned by chance to one of the two drugs and both the study team and participants know which drug is being taken. After enrollment, participants receive daily medication and attend regular clinic visits for safety checks and imaging scans that monitor the tumor. The study follows each person until the cancer shows signs of worsening, which is measured as progression-free survival, or until side effects require stopping the medication.

The purpose of the study is to find out whether giving Salanersen about six months after the gene‑therapy is safe and can be tolerated well. Children who take part will receive the injection and then be seen regularly for several years. At each visit they will have simple blood draws and brief examinations to check how they are doing.

During the study doctors will watch for any side effects and will also look at a protein called neurofilament light chain that can show nerve damage, and they will perform a test called compound muscle action potential that measures how nerves and muscles work together. The children’s ability to reach basic movement goals such as sitting, standing and walking will be recorded using the World Health Organization motor milestones and other easy‑to‑understand scales like the Hammersmith Infant Neurological Examination, CHOP INTEND, Hammersmith Functional Motor Scale Expanded and Revised Upper Limb Module. The follow‑up continues until the children are several years old, allowing researchers to see long‑term safety and any signs of benefit.

All participants receive the standard drugs in R-mini-CHOP, which include the antibody rituximab and several chemotherapy agents. In the experimental group, patients also receive epcoritamab, which is given as a small injection under the skin (subcutaneous). The standard group receives only the usual chemotherapy and the antibody given either by vein (intravenous) or under the skin, depending on the usual practice.

Participants are randomly assigned to one of the two treatment plans and go through a series of treatment cycles over several months. After the treatment period, regular check‑ups are performed to see whether the cancer has disappeared completely (called complete remission) or whether it has returned. The study follows patients for a period of time after treatment to monitor their health and any side effects.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

The main aim of the trial is to assess the long‑term safety of the study drug, meaning how well it is tolerated over time and what side effects may occur. Participants who have already finished earlier studies receive the medication for an extended period, attending regular visits where health checks, blood tests and simple scans are performed. Any unwanted problems, called adverse events, are recorded and evaluated, with particular attention to serious issues that might require medical care.

The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

The purpose of the study is to evaluate the safety of two different dose levels of the experimental medicine compared with the standard treatment. Participants are randomly assigned without knowing which medication they receive (double‑blind) and are followed for about one year after the transplant. During this time, doctors monitor for any side effects, serious side effects, or events of special interest, and they also track how well the transplanted kidney works. The study involves a series of clinic visits where blood samples are taken and routine health checks are performed, but no complex procedures are required.

The purpose of the study is to evaluate how well these new immunotherapy combinations work compared to Pembrolizumab alone in patients with a specific type of NSCLC that shows high levels of a protein called PD-L1. This protein can affect how the immune system responds to cancer. The study will involve participants receiving these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period of time to observe the effects of the treatments on their cancer.

Participants in the study will be monitored closely by healthcare professionals to ensure their safety and to gather information about how the treatments are working. The study aims to provide valuable insights into the effectiveness of these new treatment combinations for NSCLC, potentially leading to better treatment options for patients in the future.

The purpose of the study is to assess how safe the medicine is and whether it shows early signs that it can shrink tumors when used alone or with the hormone blocker. Participants start with low doses that are gradually increased while doctors watch for side effects, known as dose‑limiting toxicities, and determine the highest dose that can be given safely, called the maximum tolerated dose. After the safe dose is found, more patients receive that dose for several treatment cycles, with regular clinic visits, blood tests, and imaging scans to see if the tumors are responding. The study follows a phase 1/2 trial design, beginning with a safety‑focused part and then moving to a larger group to look at tumor response and how long the benefit lasts.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The purpose of the study is to assess the safety and tolerability of the drug. In the first part, participants receive several doses that increase in amount over time; in the second part, all participants continue to receive the drug in an open‑label phase where both researchers and participants know the treatment. Throughout the trial, researchers monitor for side effects (AEs) and perform routine checks such as a heart test (ECG), laboratory analysis of blood and the fluid around the brain and spine (CSF), vital signs, weight and mental health screening. Blood and fluid samples are also taken to understand the drug’s pharmacokinetics, meaning how it is absorbed, distributed, and cleared from the body.

Participants attend regular clinic visits over several months, during which they receive the study medication, undergo the safety checks described above, and provide samples for analysis. The study does not provide any guarantee of benefit, and its primary aim is to gather information on how the drug is tolerated in people with this condition.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

During the trial, participants will take the study medication once daily for about 24 weeks. They will attend regular clinic visits where blood samples are drawn to measure hormone levels and safety checks are performed. The study follows a straightforward schedule of visits and tests, allowing researchers to observe changes in hormone levels over time without requiring any invasive procedures.

The purpose of the study is to determine whether twice‑weekly dosing of the drug can lower protein loss in the urine compared with placebo. Participants will first receive the active medication in an open‑label phase, followed by a randomized, double‑blind phase where some receive the drug and others receive the placebo, with regular monitoring of kidney function and safety.

Throughout the trial, participants will have periodic clinic visits where urine samples are collected to calculate the urine protein to creatinine ratio and the urine albumin to creatinine ratio, both of which indicate the level of protein leakage. Blood tests will also be performed to assess the estimated Glomerular Filtration Rate, a standard measure of how well the kidneys are filtering waste. The study continues over several months to observe changes in these measurements and to ensure the treatment is safe.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

Participants will be divided by age. Those aged 6 to under 18 will be part of a double‑blind phase where neither the participants nor the doctors know who receives the drug or the placebo, followed by an open‑label phase where everyone receives the active medication. Children younger than 6 will start directly with the active drug in an open‑label part. Over the course of the study, researchers will watch for side effects and will measure simple health indicators such as oxygen saturation (SpO2), lung capacity measured as FVC, and the distance walked in six minutes (6‑min walk distance), as well as growth and quality‑of‑life questionnaires.

The main goal of the trial is to determine whether the new combination is safe and works better than current therapies. Participants will receive the assigned medicines by IV infusion in repeated cycles, with regular hospital visits for the infusions and for medical checks. Throughout the study, doctors will look for signs that tumors shrink, known as objective response, and will track how long patients live, referred to as overall survival.

After random assignment to either the experimental group or the standard‑care group, treatment continues for several weeks while imaging scans, blood tests, and questionnaires are used to assess tumor size, side effects, and quality of life. The study also measures how long the disease stays under control without getting worse, called progression‑free survival, before participants are followed for long‑term survival outcomes.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

Participants will first receive a single low dose of the medication, followed by a period of observation. After this initial phase, they may receive multiple increasing doses over several weeks, with regular clinic visits to check how the drug is processed in the body and to record any changes in seizure frequency. Samples of the fluid around the brain and spinal cord (CSF) and blood are taken to understand how the drug moves through the body, and seizure counts are recorded to see if there is any improvement. Throughout the study, doctors closely watch for any adverse events and adjust the plan as needed.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

Participants will receive their assigned medicines on a regular schedule, with IV infusions given at the clinic and oral tablets taken at home. Throughout the study, doctors will perform routine checks, imaging scans, and questionnaires to monitor tumor size, side effects, and overall health. The trial continues until a predefined number of assessments are completed or until a participant stops treatment, after which follow‑up visits assess long‑term outcomes.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The purpose of the study is to evaluate the safety of the recommended dose of this medication in the pediatric population. Children who need diagnostic or therapeutic percutaneous vascular procedures will be given the drug during the procedure and then observed for several days. Researchers will watch for any bleeding, breathing problems such as wheezing or shortness of breath, changes in kidney function, vital signs like heart rate and blood pressure, and any other side effects that may occur.

After the infusion, participants remain in the hospital for monitoring, and follow‑up checks may be scheduled to ensure recovery and to record any adverse events. The study collects information on how well the medication is tolerated, without using any comparison or placebo, and aims to provide data that could help improve care for children with this heart condition.